首页 > 最新文献

Journal of translational science最新文献

英文 中文
Pharmacological approaches to the treatment of COVID-19 patients. 治疗COVID-19患者的药理学方法
Pub Date : 2020-12-01 Epub Date: 2020-04-17
Lawrence C Sowers, Lucas S Blanton, Scott C Weaver, Randall J Urban, Charles P Mouton

The current COVID-19 pandemic has presented unprecedented challenges to the world community. No effective therapies or vaccines have yet been established. Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable.

当前,新冠肺炎疫情给国际社会带来了前所未有的挑战。目前还没有有效的治疗方法或疫苗。基于与类似冠状病毒的同源性,已经确定了几个潜在的药物靶点,并成为实验室和临床研究的重点。本综述介绍了几种候选药物的基本原理。新出现的临床数据显示,严重的COVID-19疾病与炎症反应加剧和促凝状态相关,这表明患者的治疗策略必须超越抗病毒药物。对患有合并症的弱势患者采取有效治疗方法,将大大提高COVID-19的可管理性。
{"title":"Pharmacological approaches to the treatment of COVID-19 patients.","authors":"Lawrence C Sowers,&nbsp;Lucas S Blanton,&nbsp;Scott C Weaver,&nbsp;Randall J Urban,&nbsp;Charles P Mouton","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The current COVID-19 pandemic has presented unprecedented challenges to the world community. No effective therapies or vaccines have yet been established. Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable.</p>","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543691/pdf/nihms-1604656.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38477197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plasma lipidomic profiling identifies a novel complex lipid signature associated with ischemic stroke in chronic kidney disease. 血浆脂质组学分析鉴定了一种与慢性肾脏疾病缺血性卒中相关的新型复杂脂质特征。
Pub Date : 2020-12-01 Epub Date: 2020-04-20
Farsad Afshinnia, Adil Jadoon, Thekkelnaycke M Rajendiran, Tanu Soni, Jaeman Byun, George Michailidis, Subramaniam Pennathur

Rationale and objective: Despite contribution of dyslipidemia to ischemic stroke, plasma lipidomic correlates of stroke in CKD is not studied. This study is aimed to identify plasma lipid alterations associated with stroke.

Study design: Cross sectional.

Setting and population: 214 participants of Clinical Phenotyping and Resource Biobank Core (CPROBE). Clinical data and plasma samples at the time of recruitment were obtained and used to generate lipidomic data by liquid chromatography/mass-spectrometry-based untargeted platform.

Predictors: Various levels of free fatty acids, acylcarnitines and complex lipids.

Outcome: Stroke.

Analytic approach: includes compound by compound comparison of lipids using t-test adjusted by false discovery rate in patients with and without stroke, and application of logistic regression analysis to identify independent lipid predictors of stroke and to estimate the odds associated with their various levels.

Results: Overall, we identified 330 compounds. Enrichment analysis revealed overrepresentation of differentially regulated phosphatidylcholines (PC)s and phosphatidylethanolamines (PE)s were overrepresented in stroke (P<0.001). Abundance of PC38:4, PE36:4, PC34:0, and palmitate were significantly higher, but those of plasmenyl-PE (pPE)38:2, and PE 32:2 was significantly lower in patients with stroke (p≤0.0014). After adjusting, each 1-SD increase in palmitate and PC38:4 was independently associated with 1.84 fold (95% CI: 1.06-3.20, p=0.031) and 1.84 fold (1.11-3.05, p=0.018) higher risk of stroke, respectively. We observed a significant trend toward higher abundance of PCs, PEs, pPEs, and sphingomyelins in stroke (p≤0.046).

Limitations: Small sample size; unclear, if similar changes in the same or opposite direction preceded stroke, as the cross-sectional nature of the observation does not allow determining the effect of time course on lipid alterations.

Conclusion: Differential regulation of palmitate, PCs, and PEs in patients with CKD and a history of stroke may represent a previously unrecognized risk factor and might be a target of risk stratification and modification.

理由和目的:尽管血脂异常对缺血性卒中有贡献,但CKD患者卒中的血浆脂质组学相关性尚未研究。本研究旨在确定与中风相关的血脂改变。研究设计:横断面。环境和人群:临床表型和资源生物库核心(CPROBE)的214名参与者。获得招募时的临床数据和血浆样本,并通过基于液相色谱/质谱的非靶向平台生成脂质组学数据。预测指标:不同水平的游离脂肪酸、酰基肉碱和复合脂质。结果:中风。分析方法:包括在卒中患者和非卒中患者中使用经错误发现率调整的t检验对脂质进行复合比较,并应用逻辑回归分析确定卒中的独立脂质预测因子并估计其不同水平相关的几率。结果:共鉴定出330种化合物。富集分析显示,差异调节的磷脂酰胆碱(PC)s和磷脂酰乙醇胺(PE)s在卒中中被过度代表(局限性:样本量小;尚不清楚卒中前是否有相同或相反方向的类似变化,因为观察的横断面性质不允许确定时间过程对脂质改变的影响。结论:棕榈酸盐、pc和pe在CKD和卒中史患者中的差异调节可能是以前未被认识到的危险因素,可能是危险分层和修改的目标。
{"title":"Plasma lipidomic profiling identifies a novel complex lipid signature associated with ischemic stroke in chronic kidney disease.","authors":"Farsad Afshinnia,&nbsp;Adil Jadoon,&nbsp;Thekkelnaycke M Rajendiran,&nbsp;Tanu Soni,&nbsp;Jaeman Byun,&nbsp;George Michailidis,&nbsp;Subramaniam Pennathur","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Rationale and objective: </strong>Despite contribution of dyslipidemia to ischemic stroke, plasma lipidomic correlates of stroke in CKD is not studied. This study is aimed to identify plasma lipid alterations associated with stroke.</p><p><strong>Study design: </strong>Cross sectional.</p><p><strong>Setting and population: </strong>214 participants of Clinical Phenotyping and Resource Biobank Core (CPROBE). Clinical data and plasma samples at the time of recruitment were obtained and used to generate lipidomic data by liquid chromatography/mass-spectrometry-based untargeted platform.</p><p><strong>Predictors: </strong>Various levels of free fatty acids, acylcarnitines and complex lipids.</p><p><strong>Outcome: </strong>Stroke.</p><p><strong>Analytic approach: </strong>includes compound by compound comparison of lipids using t-test adjusted by false discovery rate in patients with and without stroke, and application of logistic regression analysis to identify independent lipid predictors of stroke and to estimate the odds associated with their various levels.</p><p><strong>Results: </strong>Overall, we identified 330 compounds. Enrichment analysis revealed overrepresentation of differentially regulated phosphatidylcholines (PC)s and phosphatidylethanolamines (PE)s were overrepresented in stroke (P<0.001). Abundance of PC38:4, PE36:4, PC34:0, and palmitate were significantly higher, but those of plasmenyl-PE (pPE)38:2, and PE 32:2 was significantly lower in patients with stroke (p≤0.0014). After adjusting, each 1-SD increase in palmitate and PC38:4 was independently associated with 1.84 fold (95% CI: 1.06-3.20, p=0.031) and 1.84 fold (1.11-3.05, p=0.018) higher risk of stroke, respectively. We observed a significant trend toward higher abundance of PCs, PEs, pPEs, and sphingomyelins in stroke (p≤0.046).</p><p><strong>Limitations: </strong>Small sample size; unclear, if similar changes in the same or opposite direction preceded stroke, as the cross-sectional nature of the observation does not allow determining the effect of time course on lipid alterations.</p><p><strong>Conclusion: </strong>Differential regulation of palmitate, PCs, and PEs in patients with CKD and a history of stroke may represent a previously unrecognized risk factor and might be a target of risk stratification and modification.</p>","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38642806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obstructive sleep apnea in obese minipigs. 肥胖迷你猪的阻塞性睡眠呼吸暂停。
Pub Date : 2020-10-01 Epub Date: 2020-01-27 DOI: 10.15761/jts.1000374
Meng-Zhao Deng, Mohamed Y Abdelfattah, Michael C Baldwin, Edward M Weaver, Zi-Jun Liu

Objective: Obesity has reached epidemic proportions and is a strong risk factor for obstructive sleep apnea (OSA). However, the underlying mechanisms are poorly understood and current treatment strategies for OSA and obesity have critical limitations. Thus, establishment of an obesity-related large animal model with spontaneous OSA is imperative.

Materials and methods: Natural and sedated sleep were monitored and characterized in 4 obese (body mass index - BMI>48) and 3 non-obese (BMI<40) minipigs. These minipigs were instrumented with the BioRadio system under sedation for the wireless recording of respiratory airflow, snoring, abdominal and chest respiratory movements, electroencephalogram, electrooclulogram, electromyogram, and oxygen saturation. After instrumentation, the minipigs were placed in a dark room with a remote night-vision camera for monitoring all behaviors. Wakefulness and different sleep stages were classified, and episodes of apneas and/or hypopneas were identified during natural and/or sedated sleep.

Results: No hypopnea episodes were observed in two of the non-obese minipigs, but one non-obese minipig had 5 hypopnea events. Heavy snoring and 27-58 apnea and/or hypopnea episodes were identified in all 4 obese minipigs. Most of these episodes occurred in the rapid eye movement stage during natural sleep and/or sedated sleep in Yucatan minipigs.

Conclusions: Obese minipigs can experience naturally occurring OSA, thus are an ideal large animal model for obese-related OSA studies.

目的:肥胖已达到流行病的程度,是阻塞性睡眠呼吸暂停(OSA)的一个重要危险因素。然而,其潜在机制尚不清楚,目前针对OSA和肥胖的治疗策略存在严重局限性。因此,建立与肥胖相关的自发性OSA大型动物模型势在必行。材料与方法:对4头肥胖猪(体重指数- BMI>48)和3头非肥胖猪(BMI >48)进行自然睡眠和镇静睡眠监测,并对其进行特征描述。结果:2头非肥胖迷你猪未出现低通气事件,但1头非肥胖迷你猪出现5次低通气事件。在所有4只肥胖迷你猪中均发现重度打鼾和27-58次呼吸暂停和/或低通气发作。这些事件大多发生在尤卡坦迷你猪自然睡眠和/或镇静睡眠期间的快速眼动阶段。结论:肥胖的迷你猪可以经历自然发生的OSA,因此是肥胖相关OSA研究的理想大型动物模型。
{"title":"Obstructive sleep apnea in obese minipigs.","authors":"Meng-Zhao Deng,&nbsp;Mohamed Y Abdelfattah,&nbsp;Michael C Baldwin,&nbsp;Edward M Weaver,&nbsp;Zi-Jun Liu","doi":"10.15761/jts.1000374","DOIUrl":"https://doi.org/10.15761/jts.1000374","url":null,"abstract":"<p><strong>Objective: </strong>Obesity has reached epidemic proportions and is a strong risk factor for obstructive sleep apnea (OSA). However, the underlying mechanisms are poorly understood and current treatment strategies for OSA and obesity have critical limitations. Thus, establishment of an obesity-related large animal model with spontaneous OSA is imperative.</p><p><strong>Materials and methods: </strong>Natural and sedated sleep were monitored and characterized in 4 obese (body mass index - BMI>48) and 3 non-obese (BMI<40) minipigs. These minipigs were instrumented with the BioRadio system under sedation for the wireless recording of respiratory airflow, snoring, abdominal and chest respiratory movements, electroencephalogram, electrooclulogram, electromyogram, and oxygen saturation. After instrumentation, the minipigs were placed in a dark room with a remote night-vision camera for monitoring all behaviors. Wakefulness and different sleep stages were classified, and episodes of apneas and/or hypopneas were identified during natural and/or sedated sleep.</p><p><strong>Results: </strong>No hypopnea episodes were observed in two of the non-obese minipigs, but one non-obese minipig had 5 hypopnea events. Heavy snoring and 27-58 apnea and/or hypopnea episodes were identified in all 4 obese minipigs. Most of these episodes occurred in the rapid eye movement stage during natural sleep and/or sedated sleep in Yucatan minipigs.</p><p><strong>Conclusions: </strong>Obese minipigs can experience naturally occurring OSA, thus are an ideal large animal model for obese-related OSA studies.</p>","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38553473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Inter- and intra-individual variability of active glucagon-like peptide 1 among healthy adults 健康成年人中活性胰高血糖素样肽1的个体间和个体内变异性
Pub Date : 2020-06-16 DOI: 10.15761/jts.1000404
AC Sylvetsky, V. Bauman, J. Abdelhadi, JE Blau, K.R. Wilkins, KI Rother
Objective: To determine whether sex, age, and body mass index are correlated with active glucagon-like-peptide 1 concentrations and to investigate glucagon-like-peptide 1 reproducibility during repeated oral glucose tolerance tests. Methods: Sixty-one healthy volunteers underwent four 2-hour repeated oral glucose tolerance tests approximately 1 week apart. Because this randomized same-subject crossover trial was designed to investigate effects of non-nutritive sweeteners, participants received 355 mL (12 ounces) of water or a beverage containing non-nutritive sweeteners 10 minutes prior to each oral glucose tolerance test. Blood samples were collected 10 minutes before, and 0, 10, 20, 30, 60, 90, and 120 minutes following ingestion of 75 grams of glucose. Results: Basal active glucagon-like-peptide 1, peak glucagon-like-peptide 1, and glucagon-like-peptide 1 area-under-the-curve were higher in men than women (all p ≤0.04), adjusting for body mass index and age. Fasting and stimulated active glucagon-like-peptide 1 results were highly reproducible with little within-subject variability (between-subjects to within-subject variability ratio 4.2 and 3.5 for fasting glucagon-like-peptide 1 and glucagon-like-peptide 1 area-under-the-curve). Conclusion: Men had higher active glucagon-like-peptide 1 concentrations than women. In contrast to considerable inter-individual variability of basal and stimulated active glucagon-like-peptide 1 concentrations, intra-individual variability was low, consistent with tight physiological regulation.
目的:确定性别、年龄和体重指数是否与活性胰高血糖素样肽1浓度相关,并研究重复口服葡萄糖耐量试验中胰高血糖肽样肽1的再现性。方法:61名健康志愿者接受了4次2小时的重复口服葡萄糖耐量测试,间隔约1周。由于这项随机的同受试者交叉试验旨在研究非营养性甜味剂的影响,参与者在每次口服葡萄糖耐量测试前10分钟接受355毫升(12盎司)水或含有非营养性甜剂的饮料。在摄入75克葡萄糖之前10分钟和之后0、10、20、30、60、90和120分钟采集血样。结果:经体重指数和年龄调整后,男性的基础活性胰高血糖素样肽1、峰值胰高血糖素样肽1和胰高血糖肽样肽1曲线下面积高于女性(均p≤0.04)。禁食和刺激的活性胰高血糖素样肽1的结果具有高度可重复性,受试者内变异性很小(禁食胰高血糖素样肽1和曲线下胰高血糖肽样肽1面积的受试者与受试者间变异比为4.2和3.5)。结论:男性的活性胰高血糖素样肽1浓度高于女性。与基础和刺激的活性胰高血糖素样肽1浓度的显著个体间变异性相反,个体内变异性较低,与严格的生理调节一致。
{"title":"Inter- and intra-individual variability of active glucagon-like peptide 1 among healthy adults","authors":"AC Sylvetsky, V. Bauman, J. Abdelhadi, JE Blau, K.R. Wilkins, KI Rother","doi":"10.15761/jts.1000404","DOIUrl":"https://doi.org/10.15761/jts.1000404","url":null,"abstract":"Objective: To determine whether sex, age, and body mass index are correlated with active glucagon-like-peptide 1 concentrations and to investigate glucagon-like-peptide 1 reproducibility during repeated oral glucose tolerance tests. Methods: Sixty-one healthy volunteers underwent four 2-hour repeated oral glucose tolerance tests approximately 1 week apart. Because this randomized same-subject crossover trial was designed to investigate effects of non-nutritive sweeteners, participants received 355 mL (12 ounces) of water or a beverage containing non-nutritive sweeteners 10 minutes prior to each oral glucose tolerance test. Blood samples were collected 10 minutes before, and 0, 10, 20, 30, 60, 90, and 120 minutes following ingestion of 75 grams of glucose. Results: Basal active glucagon-like-peptide 1, peak glucagon-like-peptide 1, and glucagon-like-peptide 1 area-under-the-curve were higher in men than women (all p ≤0.04), adjusting for body mass index and age. Fasting and stimulated active glucagon-like-peptide 1 results were highly reproducible with little within-subject variability (between-subjects to within-subject variability ratio 4.2 and 3.5 for fasting glucagon-like-peptide 1 and glucagon-like-peptide 1 area-under-the-curve). Conclusion: Men had higher active glucagon-like-peptide 1 concentrations than women. In contrast to considerable inter-individual variability of basal and stimulated active glucagon-like-peptide 1 concentrations, intra-individual variability was low, consistent with tight physiological regulation.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48969486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resistance to drugs and cell death in cancer stem cells (CSCs). 癌症干细胞(CSCs)的药物耐药性和细胞死亡。
Pub Date : 2020-06-01 Epub Date: 2019-06-24 DOI: 10.15761/jts.1000341
Ahmad R Safa

Human cancers emerge from cancer stem cells (CSCs), which are resistant to cancer chemotherapeutic agents, radiation, and cell death. Moreover, autophagy provides the cytoprotective effect which contributes to drug resistance in these cells. Furthermore, much evidence shows that CSCs cause tumor initiation, progression, metastasis, and cancer recurrence. Various signaling pathways including the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), maternal embryonic leucine zipper kinase (MELK), NOTCH1, and Wnt/β-catenin as well as the CSC markers maintain CSC properties. Several mechanisms including overexpression of ABC multidrug resistance transporters, a deficiency in mitochondrial-mediated apoptosis, upregulation of c-FLIP, overexpression of anti-apoptotic Bcl-2 family members and inhibitors of apoptosis proteins (IAPs), and PI3K/AKT signaling contribute to enhancing resistance to chemotherapeutic drugs and cell death induction in CSCs in various cancers. Studying such pathways may help provide detailed understanding of CSC mechanisms of resistance to chemotherapeutic agents and apoptosis and may lead to the development of effective therapeutics to eradicate CSCs.

人类癌症起源于癌症干细胞(CSCs),它们对癌症化疗药物、辐射和细胞死亡具有抵抗力。此外,自噬提供细胞保护作用,有助于这些细胞的耐药。此外,大量证据表明,CSCs引起肿瘤的发生、进展、转移和复发。磷脂酰肌醇3-激酶(PI3K)/Akt/哺乳动物雷帕霉素靶蛋白(mTOR)、母胚亮氨酸zipper激酶(MELK)、NOTCH1和Wnt/β-catenin等多种信号通路以及CSC标志物维持CSC的特性。ABC多药耐药转运蛋白的过表达、线粒体介导的凋亡缺失、c-FLIP的上调、抗凋亡Bcl-2家族成员和凋亡蛋白抑制剂(IAPs)的过表达以及PI3K/AKT信号传导等多种机制有助于增强各种癌症中CSCs对化疗药物的耐药性和细胞死亡诱导。研究这些途径可能有助于详细了解CSC对化疗药物和细胞凋亡的耐药机制,并可能导致开发有效的治疗方法来根除CSC。
{"title":"Resistance to drugs and cell death in cancer stem cells (CSCs).","authors":"Ahmad R Safa","doi":"10.15761/jts.1000341","DOIUrl":"https://doi.org/10.15761/jts.1000341","url":null,"abstract":"<p><p>Human cancers emerge from cancer stem cells (CSCs), which are resistant to cancer chemotherapeutic agents, radiation, and cell death. Moreover, autophagy provides the cytoprotective effect which contributes to drug resistance in these cells. Furthermore, much evidence shows that CSCs cause tumor initiation, progression, metastasis, and cancer recurrence. Various signaling pathways including the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), maternal embryonic leucine zipper kinase (MELK), NOTCH1, and Wnt/β-catenin as well as the CSC markers maintain CSC properties. Several mechanisms including overexpression of ABC multidrug resistance transporters, a deficiency in mitochondrial-mediated apoptosis, upregulation of c-FLIP, overexpression of anti-apoptotic Bcl-2 family members and inhibitors of apoptosis proteins (IAPs), and PI3K/AKT signaling contribute to enhancing resistance to chemotherapeutic drugs and cell death induction in CSCs in various cancers. Studying such pathways may help provide detailed understanding of CSC mechanisms of resistance to chemotherapeutic agents and apoptosis and may lead to the development of effective therapeutics to eradicate CSCs.</p>","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40325664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Plasma lipidomic profiling identifies a novel complex lipid signature associated with ischemic stroke in chronic kidney disease 血浆脂质组学分析鉴定了一种与慢性肾脏疾病缺血性卒中相关的新型复杂脂质特征
Pub Date : 2020-04-20 DOI: 10.15761/JTS.1000419
F. Afshinnia, A. Jadoon, Thekkelnaycke M. Rajendiran, Tanu Soni, Jaeman Byun, G. Michailidis, S. Pennathur
Rationale and objective: Despite contribution of dyslipidemia to ischemic stroke, plasma lipidomic correlates of stroke in CKD is not studied. This study is aimed to identify plasma lipid alterations associated with stroke. Study design: Cross sectional. Setting and population: 214 participants of Clinical Phenotyping and Resource Biobank Core (CPROBE). Clinical data and plasma samples at the time of recruitment were obtained and used to generate lipidomic data by liquid chromatography/mass-spectrometry-based untargeted platform. Predictors: Various levels of free fatty acids, acylcarnitines and complex lipids. Outcome: Stroke. Analytic approach: includes compound by compound comparison of lipids using t-test adjusted by false discovery rate in patients with and without stroke, and application of logistic regression analysis to identify independent lipid predictors of stroke and to estimate the odds associated with their various levels. Results: Overall, we identified 330 compounds. Enrichment analysis revealed overrepresentation of differentially regulated phosphatidylcholines (PC)s and phosphatidylethanolamines (PE)s were overrepresented in stroke (P<0.001). Abundance of PC38:4, PE36:4, PC34:0, and palmitate were significantly higher, but those of plasmenyl-PE (pPE)38:2, and PE 32:2 was significantly lower in patients with stroke (p≤0.0014). After adjusting, each 1-SD increase in palmitate and PC38:4 was independently associated with 1.84 fold (95% CI: 1.06–3.20, p=0.031) and 1.84 fold (1.11–3.05, p=0.018) higher risk of stroke, respectively. We observed a significant trend toward higher abundance of PCs, PEs, pPEs, and sphingomyelins in stroke (p≤0.046). Limitations: Small sample size; unclear, if similar changes in the same or opposite direction preceded stroke, as the cross-sectional nature of the observation does not allow determining the effect of time course on lipid alterations. Conclusion: Differential regulation of palmitate, PCs, and PEs in patients with CKD and a history of stroke may represent a previously unrecognized risk factor and might be a target of risk stratification and modification.
理由和目的:尽管血脂异常对缺血性卒中有影响,但CKD患者的血浆脂质组学与卒中的相关性尚未研究。本研究旨在确定与中风相关的血脂变化。研究设计:横截面。设置和人群:214名临床表型和资源生物库核心(CPROBE)参与者。采集招募时的临床数据和血浆样本,并通过基于液相色谱/质谱的非靶向平台生成脂质组学数据。预测因素:不同水平的游离脂肪酸、酰基肉毒碱和复合脂质。结果:中风。分析方法:包括使用根据脑卒中患者和非脑卒中患者的错误发现率调整的t检验对脂质进行逐化合物比较,以及应用逻辑回归分析来确定脑卒中的独立脂质预测因子,并估计与其不同水平相关的比值。结果:我们总共鉴定了330个化合物。富集分析显示,差异调节的磷脂酰胆碱(PC)和磷脂酰乙醇胺(PE)在脑卒中中的过度表达(P<0.001)。PC38:4、PE36:4、PC34:0和棕榈酸的丰度显著较高,但纤溶酶基PE(pPE)38:2和PE 32:2在脑卒中患者中的丰度显著较低(P≤0.0014)。调整后,棕榈酸盐和PC38:4的每一个1-SD增加分别与1.84倍(95%CI:1.06–3.20,p=0.031)和1.85倍(1.11–3.05,p=0.018)的中风风险增加独立相关。我们观察到,在中风中,PC、PE、pPE和鞘磷脂的丰度显著增加(p≤0.046)。局限性:样本量小;尚不清楚,如果在中风前发生相同或相反方向的类似变化,因为观察的横截面性质不允许确定时间进程对脂质变化的影响。结论:CKD和卒中史患者棕榈酸、PC和PE的差异调节可能是一个以前未被认识的风险因素,可能是风险分层和修改的目标。
{"title":"Plasma lipidomic profiling identifies a novel complex lipid signature associated with ischemic stroke in chronic kidney disease","authors":"F. Afshinnia, A. Jadoon, Thekkelnaycke M. Rajendiran, Tanu Soni, Jaeman Byun, G. Michailidis, S. Pennathur","doi":"10.15761/JTS.1000419","DOIUrl":"https://doi.org/10.15761/JTS.1000419","url":null,"abstract":"Rationale and objective: Despite contribution of dyslipidemia to ischemic stroke, plasma lipidomic correlates of stroke in CKD is not studied. This study is aimed to identify plasma lipid alterations associated with stroke. Study design: Cross sectional. Setting and population: 214 participants of Clinical Phenotyping and Resource Biobank Core (CPROBE). Clinical data and plasma samples at the time of recruitment were obtained and used to generate lipidomic data by liquid chromatography/mass-spectrometry-based untargeted platform. Predictors: Various levels of free fatty acids, acylcarnitines and complex lipids. Outcome: Stroke. Analytic approach: includes compound by compound comparison of lipids using t-test adjusted by false discovery rate in patients with and without stroke, and application of logistic regression analysis to identify independent lipid predictors of stroke and to estimate the odds associated with their various levels. Results: Overall, we identified 330 compounds. Enrichment analysis revealed overrepresentation of differentially regulated phosphatidylcholines (PC)s and phosphatidylethanolamines (PE)s were overrepresented in stroke (P<0.001). Abundance of PC38:4, PE36:4, PC34:0, and palmitate were significantly higher, but those of plasmenyl-PE (pPE)38:2, and PE 32:2 was significantly lower in patients with stroke (p≤0.0014). After adjusting, each 1-SD increase in palmitate and PC38:4 was independently associated with 1.84 fold (95% CI: 1.06–3.20, p=0.031) and 1.84 fold (1.11–3.05, p=0.018) higher risk of stroke, respectively. We observed a significant trend toward higher abundance of PCs, PEs, pPEs, and sphingomyelins in stroke (p≤0.046). Limitations: Small sample size; unclear, if similar changes in the same or opposite direction preceded stroke, as the cross-sectional nature of the observation does not allow determining the effect of time course on lipid alterations. Conclusion: Differential regulation of palmitate, PCs, and PEs in patients with CKD and a history of stroke may represent a previously unrecognized risk factor and might be a target of risk stratification and modification.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43047889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Pharmacological approaches to the treatment of COVID-19 patients. 新冠肺炎患者治疗的药理学方法。
Pub Date : 2020-04-17 DOI: 10.15761/JTS.1000394
L. Sowers, L. Blanton, S. Weaver, R. Urban, Charles P. Mouton
The current COVID-19 pandemic has presented unprecedented challenges to the world community. No effective therapies or vaccines have yet been established. Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable.
当前新冠肺炎疫情给国际社会带来了前所未有的挑战。目前还没有建立有效的治疗方法或疫苗。根据与类似冠状病毒的同源性,已经确定了几个潜在的药物靶点,这些靶点是实验室和临床研究的重点。这篇综述介绍了几种候选药物的基本原理。新出现的临床数据显示,严重的新冠肺炎疾病与炎症反应加剧和促凝状态有关,这表明患者的治疗策略必须超越抗病毒药物。有效治疗易患合并症患者的方法将使新冠肺炎更易于控制。
{"title":"Pharmacological approaches to the treatment of COVID-19 patients.","authors":"L. Sowers, L. Blanton, S. Weaver, R. Urban, Charles P. Mouton","doi":"10.15761/JTS.1000394","DOIUrl":"https://doi.org/10.15761/JTS.1000394","url":null,"abstract":"The current COVID-19 pandemic has presented unprecedented challenges to the world community. No effective therapies or vaccines have yet been established. Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43674504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
System accuracy evaluation of the systems for selfmonitoring of blood glucose GL50 evo and GL 44 following DIN EN ISO 15197:2015 – A comparison of accuracy in hypo (<70 mg/dL)- and hyper glycemic (≥180 mg/dL) glucose ranges 根据DIN EN ISO 15197:2015对血糖自我监测系统GL50 evo和GL 44的系统准确性评估-低血糖(<70 mg/dL)和高血糖(≥180 mg/dL)血糖范围的准确性比较
Pub Date : 2020-01-01 DOI: 10.15761/JTS.1000348
E. Salzsieder, A. Puchert, EJ Freyse, S. Berg
Ongoing standardized verification of the accuracy of blood glucose meters systems for self-monitoring post-launch is important clinically and helps confirm appropriate continues performance of selfmonitoring blood glucose (SMBG) systems [1]. In addition, publication of such studies is increasingly becoming a component of evidence-based purchase decision making. ISO 15197:2015, [2] for which mandatory compliance is recommended for SMBG systems by 2015, [3] has tighter accuracy requirements than ISO 15197:2003, [4] and outlines current minimum accuracy standards necessary in Europe for CE marking. In the present study, a postmarketing evaluation of the CE-marked GL50 evo and GL44 systems were performed in accordance with ISO 15197:2015 protocols and requirements. The GL50 evo and GL44 systems were supplied in Germany from the Beurer GmbH, Germany. A declaration of conformity from the manufacturer of the two measuring systems was available before the start of the study, so that only the GL50 evo was used in the tests, but the results documented the quality of bothsystems. Two GL50 evo systems (serial number: GL55 T1 and GL55 T2) and strips from 3 different lots (A 10/1, A 10/3,A 10/4) with expiry dates March 2017 respectively) were supplied by the manufacturer. The study was
在启动后对用于自我监测的血糖仪系统的准确性进行持续的标准化验证具有重要的临床意义,并有助于确认自我监测血糖(SMBG)系统的适当持续性能[1]。此外,此类研究的发表正日益成为基于证据的购买决策的一个组成部分。ISO 15197:2015,[2],到2015年强制要求SMBG系统遵守,[3]比ISO 15197:2003,[4]有更严格的精度要求,并概述了欧洲CE标志所需的当前最低精度标准。在本研究中,根据ISO 15197:2015协议和要求,对ce标记的GL50 evo和GL44系统进行了上市后评估。GL50 evo和GL44系统由德国Beurer GmbH提供。在研究开始之前,两种测量系统的制造商有一份符合性声明,因此在测试中只使用GL50 evo,但结果记录了两种系统的质量。制造商提供了两个GL50 evo系统(序列号:GL55 T1和GL55 T2)和3个不同批次(A 10/1, A 10/3,A 10/4)的条带,有效期分别为2017年3月)。这项研究是
{"title":"System accuracy evaluation of the systems for selfmonitoring of blood glucose GL50 evo and GL 44 following DIN EN ISO 15197:2015 – A comparison of accuracy in hypo (<70 mg/dL)- and hyper glycemic (≥180 mg/dL) glucose ranges","authors":"E. Salzsieder, A. Puchert, EJ Freyse, S. Berg","doi":"10.15761/JTS.1000348","DOIUrl":"https://doi.org/10.15761/JTS.1000348","url":null,"abstract":"Ongoing standardized verification of the accuracy of blood glucose meters systems for self-monitoring post-launch is important clinically and helps confirm appropriate continues performance of selfmonitoring blood glucose (SMBG) systems [1]. In addition, publication of such studies is increasingly becoming a component of evidence-based purchase decision making. ISO 15197:2015, [2] for which mandatory compliance is recommended for SMBG systems by 2015, [3] has tighter accuracy requirements than ISO 15197:2003, [4] and outlines current minimum accuracy standards necessary in Europe for CE marking. In the present study, a postmarketing evaluation of the CE-marked GL50 evo and GL44 systems were performed in accordance with ISO 15197:2015 protocols and requirements. The GL50 evo and GL44 systems were supplied in Germany from the Beurer GmbH, Germany. A declaration of conformity from the manufacturer of the two measuring systems was available before the start of the study, so that only the GL50 evo was used in the tests, but the results documented the quality of bothsystems. Two GL50 evo systems (serial number: GL55 T1 and GL55 T2) and strips from 3 different lots (A 10/1, A 10/3,A 10/4) with expiry dates March 2017 respectively) were supplied by the manufacturer. The study was","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67490324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insulin-like growth factor 2 promotes adipocyte proliferation, differentiation and lipid deposition in obese type 2 diabetes 胰岛素样生长因子2促进肥胖型2型糖尿病中脂肪细胞增殖、分化和脂质沉积
Pub Date : 2020-01-01 DOI: 10.15761/jts.1000362
Liping Xuan, Jun Ma, Mei Yu, Zhenxing Yang, Yongmin Huang, Caiyun Guo, Yang Lu, Lidan Yan, Songqing Shi
Aim: Insulin-like growth factor-2 (IGF2) is known to regulate fetal development and differentiation, but its role in adults is still poorly understood compared with that of IGF1. This study evaluated the expression of IGF2 in obesity with type 2 diabetes mellitus (T2DM) and investigated the effects of IGF2 on adipocyte proliferation, differentiation and lipid deposition. Methods: A cross-sectional study with pair-matched controls was conducted on 50 adults with obese T2DM and 50 controls in Yuyao people's hospital, China. Serum levels of IGF2 were measured with a commercial ELISA kit. Pre-adipocytes of 3T3-L1 cell viability was determined by an MTS assay. Oil Red O staining and Nile Red staining were performed to evaluate the effects of IGF2 on 3T3-L1 differentiation and lipid deposition. Results: The expression of IGF2 is up-regulated in obese T2DM and correlates with lipid-related parameters like body mass index (r=0.315, p=0.002), waist circumference (r=0.271, p=0.008), triglyceride (r=0.262, p=0.008) and HDL-c (r=-0.324, p=0.002). Treatment of IGF2 could promote the proliferation of 3T3-L1 cells in a dose-dependent manner. High dose of IGF2 promoted 3T3-L1 differentiation by Oil Red O staining and enhanced the lipid accumulation in differentiated 3T3-L1 adipocytes by Nile Red staining and triglyceride assay. Conclusion: High level of IGF2 was positively correlated with lipid-related parameters in obeseT2DM. Furthermore, IGF2 could promote the proliferation and differentiation of 3T3-L1 cells and increase the lipid deposition of differentiated 3T3-L1 adipocytes.
目的:已知胰岛素样生长因子-2 (IGF2)调节胎儿发育和分化,但与IGF1相比,其在成人中的作用仍然知之甚少。本研究通过检测IGF2在肥胖合并2型糖尿病(T2DM)中的表达,探讨IGF2对脂肪细胞增殖、分化和脂质沉积的影响。方法:对中国余姚市人民医院50例成人肥胖型2型糖尿病患者和50例对照组进行横断面研究,并进行配对对照。用商用ELISA试剂盒检测血清IGF2水平。采用MTS法测定3T3-L1细胞前脂肪细胞的活力。采用油红O染色和尼罗红染色评价IGF2对3T3-L1分化和脂质沉积的影响。结果:IGF2在肥胖型T2DM中表达上调,并与体重指数(r=0.315, p=0.002)、腰围(r=0.271, p=0.008)、甘油三酯(r=0.262, p=0.008)、HDL-c (r=-0.324, p=0.002)等脂质相关参数相关。IGF2处理可促进3T3-L1细胞的增殖,并呈剂量依赖性。高剂量IGF2通过油红O染色促进3T3-L1的分化,并通过尼罗红染色和甘油三酯实验增强分化3T3-L1脂肪细胞的脂质积累。结论:高水平IGF2与肥胖型糖尿病血脂相关指标呈正相关。IGF2能促进3T3-L1细胞的增殖和分化,增加分化后的3T3-L1脂肪细胞的脂质沉积。
{"title":"Insulin-like growth factor 2 promotes adipocyte proliferation, differentiation and lipid deposition in obese type 2 diabetes","authors":"Liping Xuan, Jun Ma, Mei Yu, Zhenxing Yang, Yongmin Huang, Caiyun Guo, Yang Lu, Lidan Yan, Songqing Shi","doi":"10.15761/jts.1000362","DOIUrl":"https://doi.org/10.15761/jts.1000362","url":null,"abstract":"Aim: Insulin-like growth factor-2 (IGF2) is known to regulate fetal development and differentiation, but its role in adults is still poorly understood compared with that of IGF1. This study evaluated the expression of IGF2 in obesity with type 2 diabetes mellitus (T2DM) and investigated the effects of IGF2 on adipocyte proliferation, differentiation and lipid deposition. Methods: A cross-sectional study with pair-matched controls was conducted on 50 adults with obese T2DM and 50 controls in Yuyao people's hospital, China. Serum levels of IGF2 were measured with a commercial ELISA kit. Pre-adipocytes of 3T3-L1 cell viability was determined by an MTS assay. Oil Red O staining and Nile Red staining were performed to evaluate the effects of IGF2 on 3T3-L1 differentiation and lipid deposition. Results: The expression of IGF2 is up-regulated in obese T2DM and correlates with lipid-related parameters like body mass index (r=0.315, p=0.002), waist circumference (r=0.271, p=0.008), triglyceride (r=0.262, p=0.008) and HDL-c (r=-0.324, p=0.002). Treatment of IGF2 could promote the proliferation of 3T3-L1 cells in a dose-dependent manner. High dose of IGF2 promoted 3T3-L1 differentiation by Oil Red O staining and enhanced the lipid accumulation in differentiated 3T3-L1 adipocytes by Nile Red staining and triglyceride assay. Conclusion: High level of IGF2 was positively correlated with lipid-related parameters in obeseT2DM. Furthermore, IGF2 could promote the proliferation and differentiation of 3T3-L1 cells and increase the lipid deposition of differentiated 3T3-L1 adipocytes.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67490606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Decellularized scaffolds for neuronal regeneration 用于神经元再生的去细胞支架
Pub Date : 2020-01-01 DOI: 10.15761/JTS.1000371
P. Raffa, A. Urciuolo
The extracellular matrix (ECM) provides the three-dimensional structure of tissues, and is required for cell homing and cell viability, as well as for the overall homeostasis of tissues and organs [1,2]. The dynamic and complex microenvironment that the ECM generates in a specific manner for each tissue guarantees its functions [1,2]. During tissue regeneration ECM has been shown to play an essential role in controlling the tissue-stem cell compartment and to be involved in tissue regeneration outcome [3-6]. Tissue engineering combines extracellular natural and/or synthetic scaffolds (biomaterials) with stem cells and growth factors for the development of regenerative medicine strategies and the treatment of diseased tissues [7]. Despite the fact that incredible improvements have been achieved in biomaterial manufacturing, the peculiar and complex biochemistry, biomechanics and 3D organization proper of a tissue-specific ECM still cannot totally be reproduced in the lab [1,2,8]. Such complexity can however be preserved in scaffolds that take advantage of the native tissue themselves, as decellularized tissues or whole organs [9-11]. Decellularization process remove cellular and nuclear content retaining ECM mechanical integrity, biological activity and 3D architecture of the native tissue [10]. Decellularized tissues and/or organs represent alternative and promising scaffold material for the treatment of clinical cases in which extensive regeneration of an organ is required, as in cases of traumatic injuries, surgical ablation and congenital diseases [12]. Decellularized scaffolds have already been obtained from different organs and used for regenerative medicine strategies in animal models, as well as in clinical trials [12,13]. Ideally
细胞外基质(extracellular matrix, ECM)提供了组织的三维结构,是细胞归巢和细胞活力以及组织和器官整体稳态所必需的[1,2]。ECM以特定的方式为每个组织产生的动态和复杂的微环境保证了其功能[1,2]。在组织再生过程中,ECM已被证明在控制组织干细胞区室和参与组织再生结果方面发挥重要作用[3-6]。组织工程将细胞外天然和/或合成支架(生物材料)与干细胞和生长因子结合起来,用于开发再生医学策略和治疗病变组织。尽管生物材料制造已经取得了令人难以置信的进步,但组织特异性ECM的特殊和复杂的生物化学、生物力学和三维组织特性仍然无法在实验室中完全重现[1,2,8]。然而,这种复杂性可以保留在利用天然组织本身的支架中,如脱细胞组织或整个器官[9-11]。脱细胞过程去除细胞和核内容物,保留ECM的机械完整性、生物活性和天然组织[10]的3D结构。脱细胞组织和/或器官是治疗需要广泛器官再生的临床病例的替代和有前途的支架材料,如创伤性损伤、手术消融和先天性疾病bbb。脱细胞支架已经从不同器官中获得,并在动物模型和临床试验中用于再生医学策略[12,13]。在理想的情况下
{"title":"Decellularized scaffolds for neuronal regeneration","authors":"P. Raffa, A. Urciuolo","doi":"10.15761/JTS.1000371","DOIUrl":"https://doi.org/10.15761/JTS.1000371","url":null,"abstract":"The extracellular matrix (ECM) provides the three-dimensional structure of tissues, and is required for cell homing and cell viability, as well as for the overall homeostasis of tissues and organs [1,2]. The dynamic and complex microenvironment that the ECM generates in a specific manner for each tissue guarantees its functions [1,2]. During tissue regeneration ECM has been shown to play an essential role in controlling the tissue-stem cell compartment and to be involved in tissue regeneration outcome [3-6]. Tissue engineering combines extracellular natural and/or synthetic scaffolds (biomaterials) with stem cells and growth factors for the development of regenerative medicine strategies and the treatment of diseased tissues [7]. Despite the fact that incredible improvements have been achieved in biomaterial manufacturing, the peculiar and complex biochemistry, biomechanics and 3D organization proper of a tissue-specific ECM still cannot totally be reproduced in the lab [1,2,8]. Such complexity can however be preserved in scaffolds that take advantage of the native tissue themselves, as decellularized tissues or whole organs [9-11]. Decellularization process remove cellular and nuclear content retaining ECM mechanical integrity, biological activity and 3D architecture of the native tissue [10]. Decellularized tissues and/or organs represent alternative and promising scaffold material for the treatment of clinical cases in which extensive regeneration of an organ is required, as in cases of traumatic injuries, surgical ablation and congenital diseases [12]. Decellularized scaffolds have already been obtained from different organs and used for regenerative medicine strategies in animal models, as well as in clinical trials [12,13]. Ideally","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67490758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of translational science
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1